Table 1 Inhibitors of epigenetic modifications for the treatment of ovarian cancer
From: Epigenetics in ovarian cancer: premise, properties, and perspectives
Classification | Drug | Target | Phase | Reference | |
|---|---|---|---|---|---|
HDACi | Hydroxamic acid | Trichostatin A(TSA) | Class I and II HDAC families | Preclinical | [214] |
Panobinostat(LBH589) | Class I and II HDAC families | Phase I | |||
Belinostat(PXD101) | Class I and II HDAC families | Phase II | |||
Short-chain fatty acid | Valproic acid(VPA) | Class I and IIa HDAC families | Phase I and Phase III | NCT00529022; NCT00533299 | |
Cyclic peptide | Romidepsin(FK288) | Class I HDAC family | Phase II | NCT00091195(Terminated); NCT00085527(Withdrawn) | |
Benzamide | Mocetinostat(MGCD0103) | Class I HDAC family | Preclinical | [217] | |
HKMTi | S-adenosylhomocysteine hydrolase inhibitor | 3-Deazaneplanocin A(DZNEP) | Polycomb group proteins | Preclinical | [209] |
HDMTi | Polyamine analog | Polyamine analog | LSD1 | Preclinical | [218] |